




The relative strengths and weaknesses of Theravance Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theravance Biopharma Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 181% points. The greatest weakness of Theravance Biopharma Inc is the variable Intangible Assets, reducing the Economic Capital Ratio by 3.3% points.

The company's Economic Capital Ratio, given in the ranking table, is 407%, being 194% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	133,541
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,767
Liabilities, Non-Current	0
Other Assets	239,390
Other Compr. Net Income	-50
Other Expenses	11,017
Other Liabilities	0
Other Net Income	9,116
Other Revenues	57,424
Property and Equipment	9,068
Research and Development	40,621
Selling, General and Administrative Expense	70,095

Output Variable	Value in 1000 USD
Assets	381,999
Liabilities	24,767
Expenses	121,733
Revenues	57,424
Stockholders Equity	357,232
Net Income	-55,193
Comprehensive Net Income	-55,218
BaseVar	297,544
ECR before Limited Liability	356%
Economic Capital Ratio	407%